Literature DB >> 17932249

ATM kinase activity modulates Fas sensitivity through the regulation of FLIP in lymphoid cells.

Venturina Stagni1, Maria Giovanna di Bari, Silvia Cursi, Ivano Condò, Maria Teresa Cencioni, Roberto Testi, Yaniv Lerenthal, Enrico Cundari, Daniela Barilà.   

Abstract

Ataxia telangiectasia (A-T) is a rare cancer-predisposing genetic disease, caused by the lack of functional ATM kinase, a major actor of the double strand brakes (DSB) DNA-damage response. A-T patients show a broad and diverse phenotype, which includes an increased rate of lymphoma and leukemia development. Fas-induced apoptosis plays a fundamental role in the homeostasis of the immune system and its defects have been associated with autoimmunity and lymphoma development. We therefore investigated the role of ATM kinase in Fas-induced apoptosis. Using A-T lymphoid cells, we could show that ATM deficiency causes resistance to Fas-induced apoptosis. A-T cells up-regulate FLIP protein levels, a well-known inhibitor of Fas-induced apoptosis. Reconstitution of ATM kinase activity was sufficient to decrease FLIP levels and to restore Fas sensitivity. Conversely, genetic and pharmacologic ATM kinase inactivation resulted in FLIP protein up-regulation and Fas resistance. Both ATM and FLIP are aberrantly regulated in Hodgkin lymphoma. Importantly, we found that reconstitution of ATM kinase activity decreases FLIP protein levels and restores Fas sensitivity in Hodgkin lymphoma-derived cells. Overall, these data identify a novel molecular mechanism through which ATM kinase may regulate the immune system homeostasis and impair lymphoma development.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17932249     DOI: 10.1182/blood-2007-04-085399

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  14 in total

Review 1.  TRAIL and guardian angel of genome integrity: ATM boards TRAIL blazer.

Authors:  Ammad Ahmad Farooqi; Salman Waseem; Muhammad Sajjad Ashraf; Muhammed Javed Iqbal; Shahzad Bhatti
Journal:  J Cancer Res Clin Oncol       Date:  2011-06-26       Impact factor: 4.553

2.  Proteomic profiling of ATM kinase proficient and deficient cell lines upon blockage of proteasome activity.

Authors:  Valeria Marzano; Simonetta Santini; Claudia Rossi; Mirco Zucchelli; Annamaria D'Alessandro; Carlo Marchetti; Michele Mingardi; Venturina Stagni; Daniela Barilà; Andrea Urbani
Journal:  J Proteomics       Date:  2012-05-26       Impact factor: 4.044

3.  ATM kinase activity modulates ITCH E3-ubiquitin ligase activity.

Authors:  S Santini; V Stagni; R Giambruno; G Fianco; A Di Benedetto; M Mottolese; M Pellegrini; D Barilà
Journal:  Oncogene       Date:  2013-02-25       Impact factor: 9.867

4.  Targeting the Anti-Apoptotic Protein c-FLIP for Cancer Therapy.

Authors:  Ahmad R Safa; Karen E Pollok
Journal:  Cancers (Basel)       Date:  2011-06       Impact factor: 6.639

Review 5.  Tug of war between survival and death: exploring ATM function in cancer.

Authors:  Venturina Stagni; Veronica Oropallo; Giulia Fianco; Martina Antonelli; Irene Cinà; Daniela Barilà
Journal:  Int J Mol Sci       Date:  2014-03-27       Impact factor: 5.923

6.  Sp1-mediated transcriptional activation of miR-205 promotes radioresistance in esophageal squamous cell carcinoma.

Authors:  Fei Pan; Hui Mao; Fangfang Bu; Xin Tong; Jingjing Li; Sujie Zhang; Xing Liu; Lingxiong Wang; Liangliang Wu; Rui Chen; Huafeng Wei; Bohua Li; Cheng Li; Yunsheng Yang; Clifford J Steer; Jian Zhao; Yajun Guo
Journal:  Oncotarget       Date:  2017-01-24

Review 7.  Regulatory mechanisms and clinical perspectives of miRNA in tumor radiosensitivity.

Authors:  Luqing Zhao; Ann M Bode; Ya Cao; Zigang Dong
Journal:  Carcinogenesis       Date:  2012-07-12       Impact factor: 4.944

8.  Hyperthermia enhances mapatumumab-induced apoptotic death through ubiquitin-mediated degradation of cellular FLIP(long) in human colon cancer cells.

Authors:  X Song; S-Y Kim; Z Zhou; E Lagasse; Y T Kwon; Y J Lee
Journal:  Cell Death Dis       Date:  2013-04-04       Impact factor: 8.469

9.  A New Player in the Development of TRAIL Based Therapies for Hepatocarcinoma Treatment: ATM Kinase.

Authors:  Venturina Stagni; Simonetta Santini; Daniela Barilà
Journal:  Cancers (Basel)       Date:  2012-04-05       Impact factor: 6.639

10.  Ataxia-Telangiectasia Mutated Kinase: Role in Myocardial Remodeling.

Authors:  Patsy Thrasher; Mahipal Singh; Krishna Singh
Journal:  J Rare Dis Res Treat       Date:  2016-12-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.